NeOnc Technologies CEO Discusses Breakthrough Intranasal Brain Cancer Treatment

NeOnc's Novel Intranasal Drug Delivery

• 💡 NeOnc Technologies is pioneering a new method for treating aggressive brain cancers by delivering chemotherapy directly to tumors via intranasal delivery.
• 🚀 This innovative approach bypasses the blood-brain barrier, significantly reducing systemic toxicity compared to traditional oral chemotherapy.
• 🧠 The technology, built on 179 global patents from USC Keck Medical School, aims to offer a safer and more effective treatment for brain cancer patients.

Clinical Trials and Promising Data

• 🔬 NeOnc is currently conducting four clinical trials: three Phase II studies and one Phase I trial for pediatric brain cancer.
• ✅ Early data from late-stage patients shows a 24% radiographic tumor remission rate, with survival extension significantly exceeding current standards of care.
• 📈 The company expects Phase 2A readouts within the next six months, with potential for a final Phase 2B study before regulatory advancement.

Pipeline and Future Indications

• 🎯 The lead drug, NEO 100, is for glioblastomas, while NEO 212 is a bio-conjugated form of Merc's TMZ drug for all brain cancers.
• 🧩 Other pipeline candidates include NEO00-2 for meningioma and NEO-3 for pediatric brain cancers, addressing rare diseases.
• 🌟 Looking ahead, NeOnc plans to explore intranasal delivery for other CNS diseases like Parkinson's and dementia.

Regulatory and Commercialization Efforts

• 🌟 NeOnc has received FDA Fast Track designation and has applied for a Priority Review Voucher, indicating strong potential for accelerated approval.
• 🛠️ The company is actively preparing for commercialization, including packaging and manufacturing, in anticipation of regulatory milestones.
• 📈 With expanding clinical sites and a focus on patient outcomes, NeOnc is positioning itself for a potential paradigm shift in brain cancer treatment.